These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 26600088

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia.
    Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, O'Neil JP, Lal RA, Dronkers NF, Miller BL, Gorno-Tempini ML.
    Ann Neurol; 2008 Oct; 64(4):388-401. PubMed ID: 18991338
    [Abstract] [Full Text] [Related]

  • 3. Dual-phase 18F-florbetapir positron emission tomography in patients with primary progressive aphasia, Alzheimer's disease, and healthy controls: A preliminary study.
    Kuo HC, Hsiao IT, Hsieh CJ, Huang CY, Huang KL, Wai YY, Chuang WL, Kung MP, Chu YC, Yen TC, Lin KJ, Huang CC.
    J Formos Med Assoc; 2017 Dec; 116(12):964-972. PubMed ID: 28434708
    [Abstract] [Full Text] [Related]

  • 4. Amyloid PET Positivity in Different Primary Progressive Aphasia Phenotypes.
    Beaufils E, Vercouillie J, Vierron E, Cottier JP, Camus V, Mondon K, Guilloteau D, Hommet C, Ribeiro MJ.
    Clin Nucl Med; 2018 Apr; 43(4):e103-e108. PubMed ID: 29504965
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh Compound B.
    Ng SY, Villemagne VL, Masters CL, Rowe CC.
    Arch Neurol; 2007 Aug; 64(8):1140-4. PubMed ID: 17698704
    [Abstract] [Full Text] [Related]

  • 7. Technical Considerations in Brain Amyloid PET Imaging with 18F-Florbetapir.
    Trembath L, Newell M, Devous MD.
    J Nucl Med Technol; 2015 Sep; 43(3):175-84. PubMed ID: 26271806
    [Abstract] [Full Text] [Related]

  • 8. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
    Chiotis K, Carter SF, Farid K, Savitcheva I, Nordberg A, Diagnostic Molecular Imaging (DiMI) network and the Alzheimer’s Disease Neuroimaging Initiative.
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM.
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [Abstract] [Full Text] [Related]

  • 12. Benzodiazepine Use Attenuates Cortical β-Amyloid and is Not Associated with Progressive Cognitive Decline in Nondemented Elderly Adults: A Pilot Study Using F18-Florbetapir Positron Emission Tomography.
    Chung JK, Nakajima S, Shinagawa S, Plitman E, Chakravarty MM, Iwata Y, Caravaggio F, Pollock BG, Gerretsen P, Graff-Guerrero A, Alzheimer's Disease Neuroimaging Initiative.
    Am J Geriatr Psychiatry; 2016 Nov; 24(11):1028-1039. PubMed ID: 27538351
    [Abstract] [Full Text] [Related]

  • 13. Measurement of longitudinal β-amyloid change with 18F-florbetapir PET and standardized uptake value ratios.
    Landau SM, Fero A, Baker SL, Koeppe R, Mintun M, Chen K, Reiman EM, Jagust WJ.
    J Nucl Med; 2015 Apr; 56(4):567-74. PubMed ID: 25745095
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effects of beta-amyloid accumulation on neural function during encoding across the adult lifespan.
    Kennedy KM, Rodrigue KM, Devous MD, Hebrank AC, Bischof GN, Park DC.
    Neuroimage; 2012 Aug 01; 62(1):1-8. PubMed ID: 22569063
    [Abstract] [Full Text] [Related]

  • 16. Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.
    Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM, Florbetapir F 18 Study Investigators.
    J Nucl Med; 2012 Mar 01; 53(3):378-84. PubMed ID: 22331215
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.
    Int J Geriatr Psychiatry; 2015 May 01; 30(5):505-13. PubMed ID: 25043833
    [Abstract] [Full Text] [Related]

  • 19. Differential neurocognitive network perturbation in amnestic and aphasic Alzheimer disease.
    Martersteck A, Sridhar J, Rader B, Coventry C, Parrish T, Mesulam MM, Rogalski E.
    Neurology; 2020 Feb 18; 94(7):e699-e704. PubMed ID: 31969462
    [Abstract] [Full Text] [Related]

  • 20. Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
    Sperling RA, Johnson KA, Doraiswamy PM, Reiman EM, Fleisher AS, Sabbagh MN, Sadowsky CH, Carpenter A, Davis MD, Lu M, Flitter M, Joshi AD, Clark CM, Grundman M, Mintun MA, Skovronsky DM, Pontecorvo MJ, AV45-A05 Study Group.
    Neurobiol Aging; 2013 Mar 18; 34(3):822-31. PubMed ID: 22878163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.